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Background: Maternal undernutrition leads to an increased risk of metabolic disorders in offspring including
obesity and insulin resistance, thought to be due to a programmed thrifty phenotype which is inappropriate for a
subsequent richer nutritional environment. In a rat model, both male and female offspring of undernourished
mothers are programmed to become obese, however postnatal leptin treatment gives discordant results between
males and females. Leptin treatment is able to rescue the adverse programming effects in the female offspring of
undernourished mothers, but not in their male offspring. Additionally, in these rats, postnatal leptin treatment of
offspring from normally-nourished mothers programmes their male offspring to develop obesity in later life, while
there is no comparable effect in their female offspring.
Results: We show by microarray analysis of the female liver transcriptome that both maternal undernutrition and
postnatal leptin treatment independently induce a similar thrifty transcriptional programme affecting carbohydrate
metabolism, amino acid metabolism and oxidative stress genes. Paradoxically, however, the combination of both
stimuli restores a more normal transcriptional environment. This demonstrates that “leptin reversal” is a global
phenomenon affecting all genes involved in fetal programming by maternal undernourishment and leptin treatment.
The thrifty transcriptional programme was associated with pro-inflammatory markers and downregulation of adaptive
immune mediators, particularly MHC class I genes, suggesting a deficit in antigen presentation in these offspring.
Conclusions: We propose a revised model of developmental programming reconciling the male and female
observations, in which there are two competing programmes which collectively drive liver transcription. The first
element is a thrifty metabolic phenotype induced by early life growth restriction independently of leptin levels. The
second is a homeostatic set point calibrated in response to postnatal leptin surge, which is able to over-ride the
metabolic programme. This “calibration model” for the postnatal leptin surge, if applicable in humans, may have
implications for understanding responses to catch-up growth in infants. Additionally, the identification of an antigen
presentation deficit associated with metabolic thriftiness may relate to a previously observed correlation between birth
season (a proxy for gestational undernutrition) and infectious disease mortality in rural African communities.
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Alterations in nutrition during fetal and perinatal life are
linked to adverse health outcomes in offspring in adult-
hood, this being known as the Developmental Origins of
Health and Disease (DOHaD) paradigm [1]. In particu-
lar, data from epidemiological cohorts and a range of
animal models has shown that maternal undernutrition
results in an increased risk of obesity and metabolic dis-
ease in offspring in later life [2,3]. The most commonly
used model of maternal undernutrition is in the rat where
studies have utilised moderate through to severe undernu-
trition (20-70% calorie restricted diets) to examine mecha-
nisms underlying the programming of later disease risk
[4-6]. Protein undernutrition appears to be particularly
important, with low protein isocaloric diet models show-
ing similar effects to caloric restriction models in both rat
and mouse [7,8].
The adverse phenotypic outcomes, particularly those
related to metabolic abnormalities, are thought to result
in part from the mismatch between a deprived early nutri-
tional environment which programmes a “thrifty phenotype”
(also called a “predictive adaptive response”), and a richer
later environment for which this metabolic programme is
inappropriate [9-11]. In addition to the metabolic sequelae
of maternal undernutrition, in some circumstances such
deprivation can have long-lasting consequences for the
immune system, for example the greatly increased preva-
lence of infectious disease among Gambian individuals
born in the “hungry season” [12-14]. This latter result was
however not replicated in studies in rural Bangladesh or
Senegal [15,16], indicating a wide degree of heterogeneity
in the immune response to maternal undernutrition.
We have previously shown in a rat model (70% caloric
restriction) that neonatal administration of the adipokine
leptin reverses the metabolic abnormalities seen in the
offspring of undernourished mothers [17,18]. Both male
and female offspring of mothers subject to maternal under-
nutrition during pregnancy developed increased adiposity
and markers of the metabolic syndrome, particularly when
fed a high fat diet postweaning. Neonatal treatment with
leptin during a key period of developmental plasticity
(postnatal age 3-13 days) reversed the programmed pheno-
type and restored near normal metabolic parameters
[17,18]. This observation was associated with a rever-
sal of the direction of the leptin response (hereafter “leptin
reversal”) in the offspring of undernourished mothers
(‘UN offspring’). Neonatal leptin treatment increased
adult levels of 11β-HSD2 transcription in the livers of
normally-nourished pups, but decreased it in livers of the
UN offspring: similar leptin reversal effects on both tran-
scription and promoter methylation were observed for
PPARα, GR and PEPCK [19].
In this follow-up analysis, we carried out whole-
genome expression profiling of liver RNA from the femaleexperimental series previously described, in order to fully
characterise the global hepatic responses to maternal un-
dernutrition (AD/UN= ad-libitum fed or undernourished
mothers), postnatal leptin administration (Lep/Sal = leptin
or saline control given postnatally), level of postweaning
diet (Chow/HF = normal or high fat diet), and the interac-
tions between these three factors. In particular, we aimed
to determine:
1. The extent of the leptin reversal–whether it affected
all leptin-regulated genes, or a specific subset of
these.
2. Which of the genes affected by the leptin reversal
were associated with the metabolic syndrome seen
in UN/Sal/HF offspring.
3. Whether there were precursor changes seen in
UN/Sal/Chow offspring, which could potentially be
markers for those at risk of developing metabolic
syndrome and/or diabetes.
4. Whether there were other non-metabolic genes and
pathways affected by maternal undernutrition
and/or leptin reversal which might therefore be
implicated in further phenotypes, We were particularly
interested in pathways relating to immune system
regulation, given the programmed effects (in human)
of undernutrition on infectious disease prevalence.
The transcriptional data indicated a significant similarity
between the AD/Lep cohorts and the UN/Sal cohorts.
This was unexpected since the phenotypic outcomes
differ markedly between these two interventions, in a
sex-specific manner. In particular, in females UN/Sal
offspring become severely obese when fed a high fat
diet, while AD/Lep do not: the reverse is the case in
males. These transcriptional findings therefore led us to
re-examine our previously published growth curves for
both the male and female experimental series. Previously,
we had analysed the preweaning and postweaning data
separately. In this re-analysis we focus on the weaning
period itself: a critical juncture during which growing
pups take over full responsibility for their own nutritional
intake. We find that growth trajectories differ between
male and female pups during weaning, and interpret the
male and female data collectively as the consequences of
two competing programmes: a thriftiness programme
which governs the efficiency of fuel, and a homeostatic set
point governing body composition.
Results
We used Illumina oligonucleotide arrays to perform ex-
pression profiling on RNA extracted from livers of fe-
male rats in 8 treatment groups (i.e. all combinations of
ad-libitum-fed or undernourished mothers, postnatal lep-
tin treatment or saline, postweaning high fat or normal
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ANOVA analysis was used to select all genes significantly
differentially expressed in at least one of the treatment
groups. 2221/8497 (26.1%) of liver-expressed genes were
called as significant in this analysis, with 1069 of these
showing at least 1.25 fold change in transcript abundance
between the highest-and lowest-expressing treatment
groups. Three-factor ANOVA analysis was subsequently
used to categorise the genes according to which individual
experimental factors, or interactions between factors, were
significant in each case (Table 1 and Additional file 1:
Table S1).
Maternal undernutrition and postnatal leptin treatment
predominantly affect the same target set
Whether considering all significant transcripts, or only
those showing more than 1.25 fold change, the largest
group of transcriptional changes (category C) represents
the non-interacting effects of postweaning diet–unsur-
prising as diet at sacrifice directly affects the animals’
metabolic status and consequently hepatic expression
profiles. However, category AB (significant regulation by
the interaction between maternal nutrition and leptinTable 1 Numbers of significantly regulated genes,
categorised according to which factors and/or




A Maternal nutrition 368 (151) Maternal nutritional status has an
effect independent of leptin
treatment and postweaning diet
B Leptin treatment 200 (90) Leptin treatment has an effect
independent of maternal nutritional
status and postweaning diet
C Postweaning diet 990 (531) Postweaning diet has an effect
independent of maternal nutritional
status and leptin treatment
AB (2-way interaction) 949 (503) The effect of leptin treatment is
dependent on maternal nutritional
status (or vice versa)
AC (2-way interaction) 96 (18) The effect of postweaning diet is
dependent on maternal nutritional
status (or vice versa)
BC (2-way interaction) 127 (74) The effect of postweaning diet is
dependent on leptin treatment
(or vice versa)
ABC (3-way interaction) 7 (3) The effects of all three factors are
mutually dependent
Uncategorised 128 (59) Although significant changes were
detected by one-way ANOVA, no
individual factor or interaction term
was subsequently significant in a
three-factor ANOVA
Bracketed figures for each category indicate the number of genes in the
category that showed at least 1.25 fold change in transcript abundance across
the data set as a whole. Additional file 2: Table S2 shows expression data for
all genes falling into each category.treatment) contained very nearly the same number of
transcripts, indicating that (a) these two factors are able to
collectively programme transcriptional responses occur-
ring many days post-intervention, and (b) these program-
ming effects are equally as important as postweaning diet
in determining the final liver expression profile. Import-
antly, category AB contains many more genes than either
category A or B alone, indicating that maternal undernu-
trition and postnatal leptin treatment largely affect the
same genes and that these effects are mutually dependent.
Phenotypic data for the programmed cohorts also show
significant interactions between maternal diet and
postnatal leptin treatment
The phenotypic characterisation of this experimental
series was expanded and re-examined, again using three-
factor ANOVA (Additional file 2: Table S2). Importantly,
while total body fat percentage is increased as expected
by a postweaning high fat diet (postweaning diet F1,56 =
150.5, p = 1.67 × 10-17), it also shows a significant inter-
action between maternal undernutrition and postnatal
leptin treatment (AB interaction F1,56 = 22.25, p = 1.63 ×
10-5). Total body fat percentage is increased by postnatal
leptin treatment (AD/Lep) and maternal undernutrition
(UN/Sal) but decreased by the combination of both (UN/
Lep). Plasma leptin levels follow the same pattern as body
fat percent (AB interaction F1,56 = 11.32, p = 1.39 × 10
-3),
and fasting C-peptide levels also show a highly signifi-
cant AB interaction term (AB interaction F1,56 = 13.13,
p = 6.29 × 10-4) and a similar profile of dysregulation.
The AB interaction term for fasting insulin levels was just
significant before FDR correction but not significant after
correction. Plasma ghrelin and other metabolic parame-
ters (liver glycerol and triglycerides, plasma glycerol, tri-
glycerides and free fatty acids) were all predominantly
regulated by postweaning diet.
There is a complex spectrum of “reversal” interactions
between transcriptional programming by maternal
nutritional status and by postnatal leptin treatment
The interactions between maternal nutrition status and
leptin treatment could be either synergistic or opposing.
For the 949 genes in category AB, we compared the
expression change induced by leptin treatment in pups
born to UN mothers (average Lep/Sal expression ratio av-
eraged across UN cohorts) to that in pups of ad libitum
fed mothers (the same ratio averaged across AD cohorts)
to determine the interaction type. The large majority of
genes (871/949 = 91.8%) showed a “leptin reversal” pattern
where the average Lep/Sal ratio in UN cohorts was oppos-
ite in sign to that in AD cohorts. Only a small proportion
of genes showed a synergistic interaction (57/949 = 6.0%)
or a partially opposing interaction (21/949 = 2.2%), defined
as genes where the average Lep/Sal ratio in UN cohorts
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tude (synergistic) or lower magnitude (partially opposing).
Hierarchical clustering of the category AB genes was
performed to determine whether there was evidence for
a binary polyphenism as suggested by Gluckman et al.
[19]. Figure 1 is a heatmap of these 949 genes showing the
residual expression changes attributable to the combin-
ation of maternal diet and/or leptin treatment. Interacting
genes fell into six broad groups of response pattern, all of
which show “leptin reversal” since the direction of leptin-
related change is opposite in AD and UN cohorts, but
with important differences in the nature of the reversal.
Group 1 and 3 genes are induced both by maternal
undernutrition and by leptin treatment (compare USC/
H and ALC/H to ASC/H), however the combination of
both factors (compare ULC/H to ASC/H) causes either
no induction of these genes (Group 3) or even a net re-
pression (Group 1). Group 2 genes show no net effect of
maternal undernutrition on its own (compare USC/H to
ASC/H), but are induced by leptin in AD cohorts (com-
pare ALC/H to ASC/H) and repressed by leptin in UN
cohorts (compare ULC/H to USC/H). Group 4 and 5
genes are repressed by both factors acting alone, but
show a reduced repression or even a net induction when
both factors are present (opposite to groups 1 and 3).
Group 6 genes are induced specifically by the combin-
ation of both factors.Figure 1 Heatmap showing hierarchical clustering of the 949 genes w
treatment, after subtracting out the effect of postweaning diet. Line gThe vast majority of AB-interacting genes show similar
changes in AD/Lep cohorts and in UN/Sal cohorts rela-
tive to the control AD/Sal cohorts. These results there-
fore support the hypothesis of a binary polyphenism in
liver transcriptional activity, where the phenotypic switch
is seen in response both to undernutrition and to postna-
tal leptin treatment, but not the combination of both.
Functional annotation analysis of leptin reversal genes
DAVID [20] was used to collate functional annotations
into annotation groups associated with each of the identi-
fied AB-interacting gene clusters by combining data from
multiple databases including Gene Ontology, Swiss-Prot,
Uni-Prot, Protein Information Resource, InterPro and
KEGG pathways (Table 2 and Additional file 3: Table S3).
Each annotation group has an enrichment score denoting
whether it is significantly associated with any given gene
cluster (enrichment score of ≥ 2 represents a p-value ≤
0.01 after correction for multiple testing). This analysis re-
vealed several functional shifts associated with maternal
undernutrition and leptin treatment.
(a) A series of metabolic and regulatory pathways were
significantly over-represented in groups 1 and 3
(i.e. upregulated in AD/Lep and UN/Sal livers),
particularly involving mitochondrially targeted genes.
The observed shifts are consistent with thriftyith a significant interaction between maternal diet and leptin
raphs show the mean (centroid) expression profile for each cluster.
Table 2 Functional clusters over-represented among genes with a significant interaction between maternal
undernutrition and postnatal leptin treatment
Expression pattern Annotation group Genes with AB interaction
Induced by maternal undernutrition
and by leptin treatment, but not
by both combined (Groups 1 & 3)
Mitochondrially-targeted genes
(enrichment score 2.64→ 4.55)
Aadac; Aadat; Abcb11; Acat2; Acsl3; Acsl5; Adhfe1; Agtr1a; Aifm1; Ak3l1;
Aldh1b1; Aldh1l2; Atad1; Atp6v1a1; Bche; Bckdhb; Bphl; Cabc1; Clpx;
Crls1; Cry1; Cyb5r3; Cyp2r1; Dhcr24; Dhtkd1; Dnaja3; Fam82a; Fut8;
Glud1; Gm2a; Golph3; Gpam; Gpd2; Hmbs; Hmgcr; NIT2; LOC501346;
LOC685778; LOC688587; TTC19; Lrp5; Lypla1; Maoa; Maob; Me1; Mgst1;
Mpv17l; Mrpl18; Mrpl50; Mterfd3; Mtfr1; Nnt; Nsdhl; Otc; Pck2; Pdhb;
Qdpr; Rab5a; RGD1308114; RGD1309676; PEX1; MYO6; MUT; TMEM70;
Rilp; Rpl10a; Sars2; Scp2; Scrn1; Sec22b; Senp2; Sfxn5; Slc16a1; Slc25a17;
Slc35a3; Slc35b3; Sod2; St3gal6; Synj2bp; Tbc1d15; Tm7sf2; Tmpo; Tnks2;
Txndc1; Uros
Microsome/peroxisome/cytochrome
p450 pathway (enrichment score
2.03→ 4.46)
A1cf; Aadac; Abca6; Abcb11; Acsl3; Acsl5; Agl; Aifm1; Aldh1a1; Baat;
Bche; Cabc1; Cadm1; Clcn2; Cnbp; Csnk1g3; Ctsc; Cyb5r3; Cyp2d22;
Cyp2d5; Cyp2r1; Dhcr24; Dio1; Dpys; Ephx1; Erap1; Fmr1; Gbe1; Hmgcr;
Isoc1; Maoa; Mbl1; Mbl2; Me1; Mgst1; Mpv17l; Nsdhl; Nt5e; Pck2; Pgd;
Pgk1; Pipox; Ppp1r3b; Ptprf; Pygl; Rab5a; Rdh3; PEX1; GNPNAT1; Rgs16;
Sat1; Scp2; Sec22b; Slc10a1; Slc25a17; Sod2; Sord; Srd5a1; Tm7sf2;
Tmco1; Tmed5; Tnks2; Txndc1; Ugt2b; Ugt2b17; Ugt2b36
Steroid synthesis and response
(enrichment score 1.86→ 2.69)
Aadac; Abcb11; Abhd5; Acsl3; Acsl5; Afp; Agl; Agtr1a; Ak3l1; Aldh1a1;
Angptl4; Avpr1a; Baat; Bche; Bckdhb; Btg1; Cfb; Crls1; Ctsc; Cyb5r3;
Cyp2d22; Cyp2r1; Dhcr24; Dnaja3; Dnajb5; Ephx1; Erap1; Foxo1a; Fut8;
Gpam; Hmgcr; Ihh; Laptm4b; LOC501346; ANGPTL3; LOC686548;
LOC688587; Lrp5; Me1; Mgst1; Mif; Nfe2l2; Nsdhl; Osbp; Pck2; Pggt1b;
Prkaa1; Rab5a; Rcan1; RGD1560513; MYO6; STARD5; Scrn1; Sec22b;
Senp2; Serpina3m; Serpinf1; Slc34a2; Slc35a3; Smad2; Sord; Srd5a1;
St3gal6; Sult1a1; Tm7sf2; Tmpo; Tnks2; Txndc1; Uros
Starch metabolism (enrichment
score 3.09)
Adh6; Agl; Aldh1a1; Aldh1b1; Amy1a; Cyp2d22; Cyp2d5; Dpys; Ephx1;
Fut8; Gbe1; Hmbs; Maoa; Maob; Mgst1; Pygl; Rdh3; Srd5a1; St3gal6;
Ugt2a3; Ugt2b; Ugt2b10; Ugt2b17; Ugt2b36; Uros
Monosaccharide metabolism
(enrichment score 2.84)
Adh6; Agl; Aifm1; Aldh1a1; Aldh1b1; Atf4; Atp6v1a1; Bckdhb; Csnk1g3;
Cyb5r3; Dhtkd1; Dio1; Dpys; Gbe1; Gm2a; Gpd2; Hmgcr; LOC685778;
Maoa; Me1; Pck2; Pdhb; Pgd; Pgk1; Ppp1r3b; Prkaa1; Pygl; UAP1;
GNPNAT1; Sat1; Slc16a1; Sod2; Sord
Pyruvate metabolism (enrichment
score 2.23)
Acat2; Acot12; Adh6; Aldh1b1; Atf4; Gpd2; LOC685778; Me1; Pck2; Pdhb;
Pgk1; Slc16a1
Complement cascade and innate
immunity (enrichment score 0.98)
Baat; C2; Cabc1; Cadm1; Cfb; Dhcr24; Dnaja3; Erap1; F9; Ihh; LEAP2;
LOC686548; Mbl1; Mbl2; Mif; Mst1; Nrep; RGD1560513; Serpina5; Sod2
Repressed by leptin in UN offspring,
induced by leptin in control
offspring (Group2)
Metal ion binding (enrichment
score 3.00)
Aox1; Arsk; Atp2b1; Cdo1; Cnot6; Cyp2b3; Cyp3a3; Fancl; Gatad2b; Ireb2;
ZZZ3; PHF20L1; Mdm4; Msl2l1; Nr5a2; Pcgf4; Pde8a; Phospho2; Prickle1;
RGD1563633; Slc10a5; Slc30a7; Slc40a1; Thrb; Tmlhe; Trim33; Upb1;
Zfp131; Zfp410; Zfp99
Repressed by maternal undernutrition
and by leptin treatment, but not
by both combined (Groups 4 & 5)
MHC antigens and lymphocyte
activation (enrichment score
2.43→ 4.00)
Ccl5; Ccrl2; Cd69; Cd8a; Coro1a; Ctsl1; Fas; Gpsm3; Gstp1; H2-M3; Icam2;
Igh-1a; Il1b; Itgb2; Klrd1; RGD1561628; Msh2; P2ry14; SH2D1A; Rpl9; RT1-
149; RT1-A2; RT1-A3; RT1-Ba; RT1-CE15; RT1-CE7; RT1-M6-2; Sart1; Spn;
Tap2; Tnfaip8l2; Tnfsf13; Unc13d; Unc93b1; Vcam1; Wdr46; Xcl1
Ribosomal biogenesis/translational
elongation (enrichment score 2.27)
Anxa1; Bloc1s2; Cpsf3; Epb4.1 l1; Gtf2b; Hnrpab; RPL22L2; Mrps25;
Nufip1; Nup210; Polr2h; Polr2i; Polr2j; Pop4; RGD1559639; RGD1559951;
Rnasen; Rpl17; Rpl18a; Rpl9; Rps14; Rps16; Rps17; Rps27; Sart1; Snrp1c;
Tdrd3; Tubb5; Utp14a; Uxt; Wdr46
Induced by the combination of
maternal undernutrition and leptin
treatment, but not by either
factor alone (Group 6)
Ribosomal biogenesis/nucleolus
(enrichment score 4.87)
Agxt; Cct2; Cdc25a; Cdk105; Colq; Copb1; Dctn6; Epb4.1 l1; Fabp2; Ftl1;
Gabarap; Gtf2a2; Gys2; Hnrnpa1; Hspb1; Imp3; Krt10; RPL22L1;
LOC364236; RGD1563484; RPS7; RGD1564519; RGD1564606; POLR2E;
Mapre3; Med6; Mettl11a; MGC114381; Mrpl49; Myo5b; Myrip; Nbn; Pola2;
Psma6; Psma7; Psmb2; Ptk2; Ranbp1; Rassf5; WDR83; RGD1559574;
RGD1559846; RGD1561086; RPS19L1; WTAP; RGD1565170; ZCCHC17;




Cdc25a; Gadd45gip1; Mapre3; MGC114381; Nbn; Psma6; Psma7; Psmb2;
Ranbp1; Rgs10; Tp53; Usp16
Note that individual genes may be annotated within several different functional clusters. Full DAVID output for each of the six groups is given in Additional file 3:
Table S3.
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included several key enzymes involved in glycogenolysis
and glycolysis, such as glygogen debranching enzyme
(Agl), glycogen phosphorylase (Pygl), phosphoglycerate
kinase (Pgk) and two subunits of pyruvate
dehydrogenase (Pdhb and LOC685778). Also
upregulated were important enzymes for amino
acid and nitrogen metabolism, including glutamate
dehydrogenase (Glud) and ornithine transcarbamoylase
(Otc); lipid metabolism including glycerol phosphate
dehydrogenase (Gpd2), long-chain fatty acid-CoA
ligases (Acsl3 and Acsl5) and acetyl-CoA
acetyltransferase (Acat2); and oxidative stress
genes including phosphogluconate dehydrogenase
(Pgd) and mitochondrial outer membrane
glutathione S-transferase (Mgst1). Consistent with
the latter, although it did not fall into any of the
annotated functional groups in the DAVID analysis,
carbonic anhydrase 3 (Ca3) was also upregulated in
AD/Lep and UN/Sal livers.
(b) Immune-related pathways showed a concerted
pattern of change across the data set. Groups 4 and
5 (i.e. downregulated in AD/Lep and UN/Sal livers)
were enriched for genes involved in the adaptive
immune response, antigen presentation and
lymphocyte activation. Particularly striking was a
strong downregulation of MHC genes (~4-8 fold
change of several class I genes, but also some class
Ib and class II genes), and also a slight
downregulation of the Tap2 peptide transporter
necessary for antigen presentation by class I
molecules. In this light it is interesting to note that
groups 1-3 (with the opposite expression pattern)
showed a trend towards enrichment for genes
involved in the complement cascade and innate
immunity such as complement gene C2. However,
this functional group was not statistically significant
(enrichment score of 0.98, corresponding to
p-value = 0.10). We note that alpha-fetoprotein
(Afp), a specific marker for liver inflammation also
falls into group 3, although it was not annotated as
inflammation-related in the DAVID analysis.
(c) Pathways associated with ribosome biogenesis and
function were significantly over-represented in group
6 and (to a lesser extent) groups 4 and 5. Finally,
mitotic cell cycle genes showed weak over-represention
in group 6. The significance level of this was borderline,
with an enrichment score of 1.70 (p-value = 0.02).
Collectively, these obervations indicate that there is a
programmed thrifty liver phenotype in AD/Lep and UN/
Sal livers that includes increased glycogenolysis, an in-
crease in protein breakdown and fat synthesis, and a
switch away from adaptive immune function towardsinnate immunity/inflammation, together with increased
oxidative stress within the cell.
“Healthily thrifty” versus “unhealthily thrifty”: is there a
difference?
Our finding that both AD/Lep and UN/Sal treatments
appear to have similar transcriptional effects was unex-
pected, since in female rats only UN/Sal/HF develops
metabolic syndrome while AD/Lep/HF does not. We
therefore considered it possible that AD/Lep might rep-
resent a state of “healthy thriftiness”–i.e. a thrifty metab-
olism that is nevertheless under control and able to cope
with a high fat diet without developing obesity; and that
UN/Sal might represent “unhealthy thriftiness”–i.e. a
thrifty metabolism that lacks safeguards and runs out of
control when confronted with a high fat diet.
To test this possibility, we carried out a pairwise com-
parison of the AD/Lep/Chow and UN/Sal/Chow cohorts
to see if there were any expression differences which
might explain why the latter is predisposed to metabolic
syndrome. However, we found no genes that were sig-
nificantly differentially expressed (FDR p-value < 0.05)
between these two cohorts, suggesting that the differ-
ence is one of degree rather than kind. Consistent with
this, of 61 genes significantly differentially expressed (FDR
p-value < 0.05) between UN/Sal/Chow and the control
AD/Sal/Chow cohort, 58 showed the same direction of
change in AD/Lep/Chow.
Is thriftiness a consequence of growth restriction rather
than leptin signalling per se?
It is challenging to explain why the UN/Sal and AD/Lep
cohorts both show a thrifty transcriptional profile, given
that postnatal leptin administration in the latter case will
mimic excess nutrition rather than undernutrition. One
possible explanation is that the dose/response curve for
leptin is intrinsically bathtub-shaped, with adverse ef-
fects mediated both by excess and by insufficient leptin
stimulation. This would be consistent with work showing
that metabolic syndrome can be triggered by maternal
overnutrition as well as maternal undernutrition [21]. How-
ever, an alternative and in our view more attractive explan-
ation is that the commonalities in expression profiles for
these cohorts reflect a shared early life history of growth
retardation. In the case of the UN/Sal cohorts, the growth
retardation is a direct consequence of the maternal under-
nutrition, while in the case of AD/Lep cohorts it occurs
postnatally and is a secondary consequence of the leptin
treatment.
Figure 2A shows that while UN/Sal pups are severely
growth restricted in utero as a consequence of the ma-
ternal undernutrition, AD/Lep pups also show a signifi-
cant restriction in neonatal growth rate during the period
of treatment (see Additional file 4: Table S4 for raw data).
Figure 2 Growth data for selected treatment cohorts and controls from postnatal days 1 to 30. Leptin treatment (d3-13) is indicated by a
shaded background. Weaning at day 22 is indicated with a vertical line. Plotted values indicate the average weight for each cohort as a
percentage of control values: surrounding shaded areas show +/− s.e.m. at each age. A, D: Values for AD/Lep/Chow (blue) relative to AD/Sal/
Chow (black) for females (A) and males (D) demonstrate a significant growth restriction in both sexes during leptin treatment. B, E: Values for
UN/Lep/Chow (blue) relative to UN/Sal/Chow (black) for females (B) and males (E) demonstrate that in offspring of undernourished mothers
there is an even more profound growth restriction during leptin treatment. Importantly, in females, but not in males, there is a pronounced
fallback in body mass relative to control during and immediately following weaning (see text for discussion). C, F: Values for UN/Sal/Chow and
UN/Lep/Chow relative to AD/Sal/Chow for females (C) and males (F). The postweaning fallback in UN/Lep/Chow females is also seen when
measured relative to AD/Sal/Chow, therefore it is not simply a consequence of catch-up growth in UN/Sal/Chow.
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duce a 5.9 percentage point drop in body mass relative to
control, with AD/Lep body mass being 95.7% of AD/Sal at
day 3, and 89.8% of AD/Sal at day 14. Other studies have
shown that growth restriction in leptin-treated neonates is
mediated by non-hepatic effects of leptin, particularly
increased thermogenesis [22]. In the female experimental
series analysed here, although the leptin-treated animals
showed no decrease in food intake relative to saline-
treated animals during the neonatal period and are thus
not hypophagic [17], nevertheless it indicates that they
have a negative energy balance given their increased ener-
getic requirements and fail to take in sufficient nutrition
to maintain a normal growth rate.
The leptin rescue paradox: a conflict between thriftiness
and set point programming
If maternal undernutrition and postnatal leptin treat-
ment can both reprogramme liver gene expression to be
thrifty, why then does the combination of both not do
so? One possibility is that the postnatal leptin treatment
might expunge the programme set during fetal life and
then somehow fail to impose the postnatal programming
seen in AD/Lep. Figure 2B shows that the postnatal lep-
tin administration has the same growth-retarding effectsin UN/Lep as in AD/Lep, rendering this hypothesis
unlikely. In fact, the degree of growth suppression is con-
siderably greater in the UN group, suggesting that the ef-
fect of leptin is potentiated by the prior starvation
episode. If the growth restriction seen in AD/Lep is suffi-
cient to trigger hepatic reprogramming, then it is reason-
able to assume that the even greater effect in UN/Lep
should also leave the liver in a thrifty state.
Figure 2B also shows that there is a significant drop
in relative growth of the UN/Lep cohorts around wean-
ing, which first becomes visible in the 1-2 days immedi-
ately prior to separation from the dam (i.e. when the
pups begin to self-wean), and continues throughout
the following week. This juncture marks the period in
which pups take over full responsibility for their own
metabolic balance between intake and expenditure, ra-
ther than it being partly controlled by maternal milk
availability and composition. This postweaning drop
in the UN/Lep cohort is not simply due to increased
catch-up growth in UN/Sal, but reflects a genuine
drop in weight relative to AD/Sal (Figure 2C). These
observations support an explanation for the apparent
paradox in which the two growth restriction episodes
(both fetal and postnatal) in the UN/Lep cohorts do
lead to thrifty metabolic programming in the livers of
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gramming effects of leptin on food intake and energy
expenditure.
Re-interpreting existing male growth data in the light of
the female transcriptional findings
In the light of the above findings, we also re-examined
the growth data from our previously published experi-
ment on male rats ([18] and see also Additional file 4:
Table S4 for raw data). Females and males show consid-
erable differences in their programmed growth responses
to postnatal leptin administration as early as weaning,
where in males there is much less postweaning fallback
in the UN/Lep cohort (Figure 2D-F). Responses also dif-
fer greatly between adult males and females. Figure 3A
shows the absolute weight gain on HF relative to normal
chow diet for each group of males and females. For AD/
Sal, both males and females gain comparable amounts
on a HF diet (37 g and 43 g respectively). Similarly, for
UN/Sal, both males and females gain a larger amount on
the HF diet (63 g and 70 g respectively). For AD/Lep,
females gain 32 g on the HF diet while males gain
100 g. Finally, for UN/Lep, females show an efficient res-
cue, bringing the weight gain back down to 35 g (from 63
in UN/Sal): by contrast males show no rescue, instead
gaining 109 g, the highest of any treatment cohort.Figure 3 Comparison of selected male and female growth data.
A: Bar chart showing average weight in g +/− s.e.m. for all cohorts
at day 108. Numbers in grey indicate the absolute weight gain on
HF diet relative to chow diet for the AD/Sal, AD/Lep, UN/Sal and
UN/Lep groups. B: Bar chart showing weight of UN/Sal/Chow (U)
relative to AD/Sal/Chow (A) at day 30 and day 108. Left = females,
right =males.The pathogenic programming effects of maternal un-
dernutrition are also more severe in males than females,
in that they are not restricted to males on the HF diet.
Figure 3C shows the weight of UN/Sal/Chow cohorts
relative to control AD/Sal/Chow for males and females at
day 30 and at the end of the experimental period. Females
and males both showed a substantial growth restriction
(see also Figure 2C, F) that is somewhat more severe in
males (82.9% ±3.7%) than females (88.0% ± 1.3%) at day
30. These males then showed a continued slow weight
gain throughout life relative to control, reaching 96.1 ±
4.8% of control by day 108–note that this was the end of
the male experimental series. In contrast, the females
maintained a stable weight relative to control from day 30
onwards (92.3% ± 1.3% on day 108, and 89.8% ± 2.4% on
day 171–the end of the female experiment).
Collectively, these results suggest that while the patho-
genic “thrift-inducing” effects of early growth restriction
are shared between males and females, the non-hepatic
mechanisms underlying the leptin rescue in UN/Lep co-
horts may be less effective (or even absent) in males com-
pared to females. In the Discussion (below) we propose a
revised and extended model for developmental program-
ming, which reconciles the hitherto-conflicting male and
female growth data.
Genes associated with the prevention of metabolic
syndrome by leptin treatment in the UN/Lep/HF cohort
Although the AD/Lep cohorts globally show many of
the same metabolic and transcriptional changes as the
UN/Sal cohorts, nevertheless in females metabolic syn-
drome is only triggered in UN/Sal/HF cohort and is pre-
vented by postnatal leptin treatment (“leptin rescue”) in
UN/Lep/HF. It is important to determine the hepatic
transcriptional changes associated with the leptin rescue,
since these may be useful biomarkers for metabolic syn-
drome and/or for the predisposed state seen in UN/Sal/
Chow. Genes of interest in this regard are those that show
a significant perturbation in expression associated with
metabolic syndrome, which is exacerbated by maternal
undernutrition and rescued by postnatal leptin treatment.
To identify these genes, we took the initial set of 2221
genes showing at least some significant change in the one-
way ANOVA and imposed three further filters:
 Maternal diet and leptin treatment both called as
significant, either individually or as part of an
interaction term. 1010 genes passed this filter; the 949
genes with a significant AB interaction plus a further 61
genes where both factors were individually significant
but the AB interaction term was not significant.
 At least a 1.25 fold change in expression level between
the affected UN/Sal/HF cohort and the control
AD/Sal/Chow cohort. 177 genes passed this filter.
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with metabolic syndrome must fall at an extreme
(highest or lowest expression amongst all 8
experimental cohorts). This yielded a final set of 98
genes, 56 of which were upregulated in metabolic
syndrome and 42 downregulated (Table 3 and
Additional file 5: Table S5).
DAVID analysis of the resulting gene list (see Additional
file 5: Table S5) reveals significant deregulation of carbo-
hydrate metabolic pathways (enrichment factor 2.939,
p-value = 0.00115), steroid response genes (enrichment
factor 1.59, p-value = 0.0256) and mitochondrially-targeted
genes (enrichment factor 1.53, p-value = 0.0298).
There was no significant enrichment for functional
terms relating to immune function in this list since the
significant downregulation of MHC class I was more pro-
nounced in AD/Lep cohorts than in UN/Sal cohorts and
hence these were excluded by the final filter (the same ap-
plies to the upregulation of complement gene C2). It is at
present unclear why postnatal leptin treatment should
have such a marked effect on immune parameters.
Precursor changes in chow-fed cohorts may be associated
with disease predisposition
Of the four chow-fed cohorts, none directly shows meta-
bolic syndrome, however the UN/Sal/Chow cohort is
predisposed to metabolic syndrome and will suffer from
it if fed a HF diet. We therefore looked specifically
within the chow-fed cohorts to determine whether any
of the 98 genes associated with metabolic syndrome
(and rescued by leptin treatment) showed precursor ex-
pression changes that might be involved in susceptibility
to or initiation of metabolic syndrome. In all, 41/98 of
these genes also showed at least a 1.25 fold expression
change in the UN/Sal/Chow cohort relative to the con-
trol AD/Sal/Chow cohort (highlighted in bold in Table 3).
For these precursor changes, DAVID analysis did not
show any enrichment for mitochondrially-targeted genes
or for steroid response genes, however the annotation
group relating to carbohydrate metabolism remained sig-
nificant (enrichment factor 2.71, p-value = 0.002).
Discussion
In this study, we present a whole-genome fully factorial
examination of the transcriptional consequences of the
interactions between maternal diet, leptin treatment,
postweaning diet and metabolic syndrome in a rat model
of developmental programming.
Our data confirm the prior observation of “leptin re-
versal”, in that of the genes regulated by postnatal leptin
treatment, the vast majority show the opposite direction
of leptin-induced change in pups born to undernour-
ished mothers, when compared to those born to normally-nourished mothers. Strikingly, it is not simply that
maternal undernutrition reverses the direction of the
leptin response: rather it appears that both maternal
undernutrition and postnatal leptin treatment inde-
pendently switch the liver into an altered state. Para-
doxically, the combination of both factors abolishes this
effect and switches the liver back into a state more closely
resembling the control (untreated) cohorts. This pattern is
seen in both the transcriptional data and in key pheno-
typic parameters relating to metabolic status.
A revised model for developmental programming of
obesity
Based on the transcriptional findings reported above and
on our re-examination of existing growth data for both
male and female offspring, we propose a revised model
of developmental programming by maternal undernutri-
tion and postnatal leptin treatment. In this new model,
there are two competing programmes that can be estab-
lished quasi-independently. The first programme is a
thrifty hepatic metabolic programme induced by early
life growth restriction, governing the efficiency with
which fuel is used by the body. Importantly, in the AD/
Lep cohorts the thrifty programming is invoked even in
the presence of a supraphysiological leptin stimulus, sug-
gesting that leptin itself is not the predominant signal in-
volved in programming of hepatic metabolic efficiency. The
second programme is a homeostatic set point programme
governing body composition that is established in response
to leptin stimulation during early neonatal life. The calibra-
tion of the set point (either lean or normal body compos-
ition) is determined by the body’s composition at the time
of leptin stimulation, while the robustness with which
the programme is “locked in” depends on the level of the
stimulus. Given the known effects of leptin on appetite and
locomotor activity, it is likely that this second programme
is mediated at least in part by centrally controlled adjust-
ment of calorie intake and expenditure, however we cannot
rule out effects of leptin in other non-hepatic tissues.
Our model is based on the emerging view that during
development leptin functions as an anti-starvation sig-
nal, as distinct from its adult role as a fatness and sa-
tiety signal [23]. During early development, in normally
nourished animals, leptin levels are high (known as the
“leptin surge”) and largely independent of fat mass. As
development proceeds, leptin levels drop to a lower
level governed dually by overall fat mass and satiety
[24-26]. Early life undernutrition delays or abolishes
the leptin surge [27,28], and nutritional recovery re-
stores it [29]–in the latter study, higher leptin levels
were observed in “recovered” infants than in control
infants, which we argue may represent a delayed de-
velopmental surge rather than a simple restoration of
leptin secretion following fat gain.
Table 3 Genes which show a significant interaction between maternal nutritional status and postnatal leptin treatment
effects, an expression change of at least 1.25 fold in the UN/Sal/HF cohort (with metabolic syndrome), and where this








Ifit1 2.95 3.52 AB 56824 Rattus norvegicus interferon-induced protein with tetratri-
copeptide repeats 1 (Ifit1), mRNA.
Ppp1r3b 1.46 2.40 AB, C 192280 Rattus norvegicus protein phosphatase 1, regulatory
(inhibitor) subunit 3B (Ppp1r3b), mRNA.
Ca3 1.29 2.38 AB, C 54232 Rattus norvegicus carbonic anhydrase 3 (Ca3), mRNA.
Stac3 1.27 2.35 AB, C 362895 PREDICTED: Rattus norvegicus SH3 and cysteine rich
domain 3 (predicted) (Stac3_predicted), mRNA.
TUBB2A 1.79 2.33 AB, BC 498736 PREDICTED: Rattus norvegicus similar to tubulin, beta 2
(TUBB2A), mRNA.
LEAP2 1.52 2.29 AB, C 497901 PREDICTED: Rattus norvegicus similar to Liver-expressed
antimicrobial peptide 2 precursor (LEAP-2) (LEAP2),
mRNA.
Slc34a2 1.45 1.88 AB, C 84395 Rattus norvegicus solute carrier family 34 (sodium
phosphate), member 2 (Slc34a2), mRNA.
Pgd 1.24 1.77 AB 362660 PREDICTED: Rattus norvegicus phosphogluconate
dehydrogenase (Pgd), mRNA.
Afp 1.33 1.76 AB, C 24177 Rattus norvegicus alpha-fetoprotein (Afp), mRNA.
VNN3 1.17 1.70 AB, C 498992 PREDICTED: Rattus norvegicus similar to Vanin-3 (predicted)
(VNN3_predicted), mRNA.
Avpr1a 1.42 1.70 AB, C 25107 Rattus norvegicus arginine vasopressin receptor 1A
(Avpr1a), mRNA.
Laptm4b 0.94 1.68 AB 315047 Rattus norvegicus lysosomal-associated protein transmembrane
4B (Laptm4b), mRNA.
Igf2bp3 1.23 1.67 AB, C 312320 PREDICTED: Rattus norvegicus insulin-like growth factor 2, bind-
ing protein 3 (Igf2bp3), mRNA.
Aldh1b1 1.08 1.64 AB, C 298079 Rattus norvegicus aldehyde dehydrogenase 1 family, member
B1 (Aldh1b1), nuclear gene encoding mitochondrial protein,
mRNA.
Amy1a 1.33 1.64 AB, C 24203 Rattus norvegicus amylase, alpha 1A (salivary) (Amy1a),
mRNA.
Aadac 1.19 1.62 AB, C 57300 Rattus norvegicus arylacetamide deacetylase (esterase) (Aadac),
mRNA.
Pipox 1.56 1.60 AB, BC 303272 Rattus norvegicus pipecolic acid oxidase (Pipox), mRNA.
Sez6 1.28 1.58 AB, C 192247 PREDICTED: Rattus norvegicus seizure related 6 homolog
(mouse) (Sez6), mRNA.
Olr59 1.31 1.56 AB, C 170816 Rattus norvegicus olfactory receptor 59 (Olr59), mRNA.
RGD1563713 1.31 1.56 AB 316550 PREDICTED: Rattus norvegicus similar to Rab18
(RGD1563713), mRNA.
Gpd2 1.28 1.56 AB, C 25062 Rattus norvegicus glycerol-3-phosphate dehydrogenase 2,
mitochondrial (Gpd2), nuclear gene encoding mitochondrial
protein, mRNA.
Bche 1.20 1.51 AB, C 65036 Rattus norvegicus butyrylcholinesterase (Bche), mRNA.
Otc 1.32 1.51 AB, C 25611 Rattus norvegicus ornithine carbamoyltransferase (Otc),
nuclear gene encoding mitochondrial protein, mRNA.
Dnmt3b 0.95 1.51 AB, AC, BC 444985 Rattus norvegicus DNA methyltransferase 3B (Dnmt3b), mRNA.
Clpx 1.35 1.50 AB, BC 300786 Rattus norvegicus ClpX caseinolytic peptidase X homolog
(E. coli) (Clpx), mRNA.
Slc7a7 1.03 1.49 AB, C 83509 Rattus norvegicus solute carrier family 7 (cationic amino acid
transporter, y + system), member 7 (Slc7a7), mRNA.
Dpys 1.04 1.49 AB, C 65135 Rattus norvegicus dihydropyrimidinase (Dpys), mRNA.
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effects, an expression change of at least 1.25 fold in the UN/Sal/HF cohort (with metabolic syndrome), and where this
cohort is an outlier from the other experimental groups (Continued)
Fam82a 1.34 1.48 AB, C 313840 Rattus norvegicus family with sequence similarity 82,
member A (Fam82a), mRNA.
Slc16a1 1.15 1.41 AB 25027 Rattus norvegicus solute carrier family 16 (monocarboxylic acid
transporters), member 1 (Slc16a1), mRNA.
Adhfe1 1.32 1.40 AB, C 362474 Rattus norvegicus alcohol dehydrogenase, iron
containing, 1 (Adhfe1), mRNA.
Inhba 1.10 1.40 AB, BC 29200 Rattus norvegicus inhibin beta-A (Inhba), mRNA.
TMEM70 1.13 1.38 AB, C 500384 PREDICTED: Rattus norvegicus similar to RIKEN cDNA
2210416 J16 (predicted) (TMEM70_predicted), mRNA.
RGD1560797 1.08 1.38 A, BC 306115 PREDICTED: Rattus norvegicus similar to glyceraldehyde-3-
phosphate dehydrogenase (predicted) (RGD1560797_pre-
dicted), mRNA.
RGD1310209 1.08 1.35 AB, C 362019 PREDICTED: Rattus norvegicus similar to KIAA1324 protein
(predicted) (RGD1310209_predicted), mRNA.
Maob 1.24 1.34 AB 25750 Rattus norvegicus monoamine oxidase B (Maob), nuclear gene
encoding mitochondrial protein, mRNA.
Lrp5 1.09 1.34 AB 293649 PREDICTED: Rattus norvegicus low density lipoprotein receptor-
related protein 5 (predicted) (Lrp5_predicted), mRNA.
Klrg1 1.10 1.34 AB, C 58975 Rattus norvegicus killer cell lectin-like receptor subfamily G,
member 1 (Klrg1), mRNA.
Atf4 1.24 1.33 AB 79255 Rattus norvegicus activating transcription factor 4 (tax-
responsive enhancer element B67) (Atf4), mRNA.
Phf11 1.15 1.33 AB, C 361051 PREDICTED: Rattus norvegicus PHD finger protein 11
(predicted) (Phf11_predicted), mRNA.
Rora 1.25 1.33 AB 300807 PREDICTED: Rattus norvegicus RAR-related orphan receptor
alpha (predicted) (Rora_predicted), mRNA.
Serpina3m 1.17 1.32 AB, C 299276 PREDICTED: Rattus norvegicus serine (or cysteine) proteinase
inhibitor, clade A, member 3 M (Serpina3m), mRNA.
PLBD1 1.15 1.31 AB, C 297694 Rattus norvegicus similar to RIKEN cDNA 1100001H23 (PLBD1),
mRNA.
ANGPTL3 1.17 1.31 AB, C 502970 PREDICTED: Rattus norvegicus similar to angiopoietin-related
protein 3 (ANGPTL3), mRNA.
Agtr1a 1.02 1.30 AB 24180 Rattus norvegicus angiotensin II receptor, type 1 (AT1A)
(Agtr1a), mRNA.
Apon 1.09 1.30 AB, C 304603 Rattus norvegicus apolipoprotein N (Apon), mRNA.
Lgals5 1.21 1.29 AB 25475 Rattus norvegicus lectin, galactose binding, soluble 5 (Lgals5),
mRNA.
Cabc1 1.23 1.28 AB 360887 Rattus norvegicus chaperone, ABC1 activity of bc1 complex
homolog (S. pombe) (Cabc1), nuclear gene encoding
mitochondrial protein, mRNA.
Sdcbp 1.12 1.27 AB 83841 Rattus norvegicus syndecan binding protein (Sdcbp), mRNA.
CP 1.07 1.27 AB 294942 PREDICTED: Rattus norvegicus hypothetical CP (CP), mRNA.
Irf6 1.14 1.26 AB 364081 PREDICTED: Rattus norvegicus interferon regulatory factor 6
(predicted) (Irf6_predicted), mRNA.
Hsd17b13 1.07 1.26 AB, C 305150 PREDICTED: Rattus norvegicus hydroxysteroid (17-beta)
dehydrogenase 13 (Hsd17b13), mRNA.
Mst1 1.17 1.26 AB 24566 Rattus norvegicus Macrophage stimulating 1 (hepatocyte
growth factor-like) (Mst1), mRNA.
Btg1 1.13 1.25 AB, C 29618 Rattus norvegicus B-cell translocation gene 1, anti-proliferative
(Btg1), mRNA.
MUT 1.19 1.25 AB 497857 PREDICTED: Rattus norvegicus similar to MYLE protein
(Dexamethasone-induced protein) (predicted) (MUT_predicted),
mRNA.
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effects, an expression change of at least 1.25 fold in the UN/Sal/HF cohort (with metabolic syndrome), and where this
cohort is an outlier from the other experimental groups (Continued)
Pxmp4 −1.38 −3.51 AB 282634 Rattus norvegicus peroxisomal membrane protein 4
(Pxmp4), mRNA.
Igfbp2 −2.11 −3.09 AB, C 25662 Rattus norvegicus insulin-like growth factor binding
protein 2 (Igfbp2), mRNA.
Sds −1.54 −2.49 AB 25044 Rattus norvegicus serine dehydratase (Sds), mRNA.
Tnfsf13 −2.22 −2.42 AB 287437 Rattus norvegicus tumor necrosis factor (ligand)
superfamily, member 13 (Tnfsf13), mRNA.
Hnrpab −1.19 −2.09 AB, C 83498 Rattus norvegicus heterogeneous nuclear ribonucleoprotein
A/B (Hnrpab), mRNA.
Asl −1.33 −2.07 AB, C 59085 Rattus norvegicus argininosuccinate lyase (Asl), mRNA.
Cd63 −1.36 −1.94 AB, C 29186 Rattus norvegicus CD63 antigen (Cd63), mRNA.
RGD1560687 −1.25 −1.85 AB, C 500804 PREDICTED: Rattus norvegicus similar to Ferritin light
chain (Ferritin L subunit) (predicted)
(RGD1560687_predicted), mRNA.
Trpm6 −1.27 −1.76 AB, C 293874 PREDICTED: Rattus norvegicus transient receptor potential
cation channel, subfamily M, member 6 (predicted)
(Trpm6_predicted), mRNA.
Hspb1 −1.34 −1.68 AB, C 24471 Rattus norvegicus heat shock 27 kDa protein 1 (Hspb1),
mRNA.
Ftl1 −1.11 −1.60 AB, C 29292 Rattus norvegicus ferritin light chain 1 (Ftl1), mRNA.
Mgst2 −1.43 −1.54 AB, BC 295037 PREDICTED: Rattus norvegicus microsomal glutathione
S-transferase 2 (predicted) (Mgst2_predicted), mRNA.
Znf593 −1.19 −1.53 AB, C 298546 PREDICTED: Rattus norvegicus zinc finger protein 593
(predicted) (Znf593_predicted), mRNA.
Ppcs −1.43 −1.52 AB, C 298490 Rattus norvegicus phosphopantothenoylcysteine
synthetase (Ppcs), mRNA.
Mthfd1 −1.38 −1.47 A, BC 64300 Rattus norvegicus methylenetetrahydrofolate
dehydrogenase (NADP + dependent) 1,
methenyltetrahydrofolate cyclohydrolase,
formyltetrahydrofolate synthetase (Mthfd1), mRNA.
Pmm1 −1.26 −1.47 A, B, C 300089 Rattus norvegicus phosphomannomutase 1 (Pmm1),
mRNA.
Aqp11 −1.35 −1.45 AB 286758 Rattus norvegicus aquaporin 11 (Aqp11), mRNA.
Csrp2 −1.34 −1.45 A, B, C 29317 Rattus norvegicus cysteine and glycine-rich protein 2
(Csrp2), mRNA.
Pla2g12a −1.27 −1.44 AB, BC 362039 PREDICTED: Rattus norvegicus phospholipase A2, group
XIIA (predicted) (Pla2g12a_predicted), mRNA.
Tifa −1.24 −1.42 AB, C 310877 Rattus norvegicus TRAF-interacting protein with
forkhead-associated domain (Tifa), mRNA.
Hexb −1.17 −1.41 AB, C 294673 Rattus norvegicus hexosaminidase B (Hexb), mRNA.
Rps14 −1.15 −1.41 AB, C 29284 Rattus norvegicus ribosomal protein S14 (Rps14), mRNA.
Ier3 −1.38 −1.40 AB 294235 Rattus norvegicus immediate early response 3 (Ier3),
mRNA.
Paics −1.40 −1.40 AB 140946 Rattus norvegicus phosphoribosylaminoimidazole
carboxylase, phosphoribosylaminoimidazole
succinocarboxamide synthetase (Paics), mRNA.
Txnl5 −1.32 −1.38 AB 287474 PREDICTED: Rattus norvegicus thioredoxin-like 5
(predicted) (Txnl5_predicted), mRNA.
Pla1a −1.35 −1.38 AB 85311 Rattus norvegicus phospholipase A1 member A (Pla1a),
mRNA.
Cyp8b1 −1.08 −1.37 AB, C 81924 Rattus norvegicus cytochrome P450, family 8, subfamily b,
polypeptide 1 (Cyp8b1), mRNA.
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effects, an expression change of at least 1.25 fold in the UN/Sal/HF cohort (with metabolic syndrome), and where this
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Creb3 −1.28 −1.36 AB, C 298400 Rattus norvegicus cAMP responsive element binding
protein 3 (Creb3), mRNA.
Cd320 −1.06 −1.36 AB, C 362851 PREDICTED: Rattus norvegicus CD320 antigen (Cd320), mRNA.
Nola2 −1.10 −1.34 AB, C 287273 PREDICTED: Rattus norvegicus nucleolar protein family A,
member 2 (predicted) (Nola2_predicted), mRNA.
Sult1c1 −0.87 −1.32 AB 65185 Rattus norvegicus sulfotransferase family, cytosolic, 1C,
member 1 (Sult1c1), mRNA.
Slc11a2 −1.16 −1.32 AB, BC 25715 Rattus norvegicus solute carrier family 11 (proton-coupled
divalent metal ion transporters), member 2 (Slc11a2), mRNA.
Btbd9 −1.19 −1.31 A, BC 294318 Rattus norvegicus BTB (POZ) domain containing 9 (Btbd9),
mRNA.
Htatip2 −1.20 −1.30 AB, C 292935 PREDICTED: Rattus norvegicus HIV-1 tat interactive protein 2,
homolog (human) (predicted) (Htatip2_predicted), mRNA.
Ctsl1 −1.09 −1.29 AB, C 25697 Rattus norvegicus cathepsin L1 (Ctsl1), mRNA.
Psmb3 −1.14 −1.29 AB, C 29676 Rattus norvegicus proteasome (prosome, macropain) subunit,
beta type 3 (Psmb3), mRNA.
Sat2 −1.16 −1.29 AB 360547 PREDICTED: Rattus norvegicus spermidine/spermine N1-acetyl
transferase 2 (predicted) (Sat2_predicted), mRNA.
Gtf2b −1.15 −1.29 AB, C 81673 Rattus norvegicus general transcription factor IIB (Gtf2b),
mRNA.
Eppb9 −1.10 −1.26 AB, BC 287383 PREDICTED: Rattus norvegicus endothelial precursor protein B9
(predicted) (Eppb9_predicted), mRNA.
Sdf2 −1.05 −1.26 AB 287470 PREDICTED: Rattus norvegicus stromal cell derived factor 2
(predicted) (Sdf2_predicted), mRNA.
Wdr45 −1.17 −1.26 AB, C 302559 Rattus norvegicus WD repeat domain 45 (Wdr45), mRNA.
Psma5 −1.20 −1.26 AB, C 29672 Rattus norvegicus proteasome (prosome, macropain) subunit,
alpha type 5 (Psma5), mRNA.
Bold indicates genes where the expression change in the UN/Sal/Chow cohort (predisposed to metabolic syndrome) is also at least 1.25 fold, indicating that
precursor changes are occurring in this group also. Additional file 5: Table S5 is an expanded version of this table containing further annotation relating to gene
ontology, gene function and known human diseases related to these genes.
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signalling is to train the homeostatic set point mecha-
nisms to recognise and subsequently maintain an appro-
priate body fat composition, and that this pattern (surge
followed by drop) represents the calibration mechanism
for the feedback loop. The peak of the leptin surge trig-
gers developments underpinning set point programming,
while the leptin levels immediately subsequent to the
surge set the baseline which will subsequently be
defended by the newly-calibrated set point program. If
the individual is normal weight at the time of the leptin
surge, a normal calibration is established and will subse-
quently be maintained. Under starvation conditions the
calibration process would normally be delayed by mech-
anisms including lower overall leptin secretion and also
competition by excess soluble leptin receptor [29]–how-
ever if exogenous leptin is administered, the combination
of a leptin surge with an underweight body composition
means that an unusually lean calibration is established
and will subsequently be maintained. Conversely, if theindividual is overweight at the time of the leptin surge, the
calibration is set inappropriately high.
Interpreting the differences between male and female
responses to early programming
Our existing growth data for male rats suggests that the
homeostatic set point mechanism is less efficient in
males than in females. Interestingly, in human babies
there is a sex difference in favour of higher leptin con-
centrations in female newborns [26], which is consistent
with our above hypothesis about the function of the lep-
tin surge in set point calibration. Incorporating this final
factor leads to the unified model described in Table 4,
which summarises the key elements of our new model
and how it relates to the observed phenotypes in both
sexes. Briefly, the first, hepatic element of the programme
(i.e. thrifty use of fuel) is induced by early life growth
restriction irrespective of the reason for that growth re-
striction, and as such all except the AD/Sal cohorts are
programmed to be thrifty. The second, leptin-mediated
Table 4 Unified model for how the competing hepatic thriftiness and non-hepatic set point programmes interact to
produce the observed phenotypes in males and females
Cohort Metabolism1 Set point calibration2 Set point enforcement3 Phenotypic consequences
♀ AD/Sal Normal Normal Strong (female default) Baseline for chow and high fat diet regimes in females.
AD/Lep Thrifty Normal Strong (female default) Normal set point calibration is enforced and overrides the thrifty
metabolism. Weight remains comparable to AD/Sal females on
both low and high fat diets despite thrifty liver biochemistry.
UN/Sal Thrifty Lean Impaired (due to
insufficient leptin
availability)
Set point enforcement is impaired and consequently unable to
compensate for a thrifty metabolism when fed a HF diet. UN/Sal/HF
females become morbidly obese and suffer metabolic syndrome.
UN/Lep Thrifty Lean Strong (restored to
female default level)
A well-enforced “lean” set point in rescued females compensates for the
thrifty metabolism, enforcing a lean body composition in UN/Lep/Chow
and keeping weight gain down to normal levels in UN/Lep/HF.
♂ AD/Sal Normal Normal Weak (male default) Baseline for chow and high fat diet regimes in males.
AD/Lep Thrifty Normal Weak (male default) As with UN/Sal animals (male and female), set point enforcement
is weak and cannot compensate for the thrifty metabolism.
The AD/Lep HF phenotype is more severe than UN/Sal/HF
because the set point is higher.
UN/Sal Thrifty Lean Severely impaired
(weak male default is
lowered further)
Set point enforcement is severely impaired and thus UN/Sal males
cannot maintain a steady body composition even on a normal
chow diet. However, the set point is still lean and so the
phenotype on HF diet is less severe than AD/Lep males.
UN/Lep Thrifty Lean Weak (restored to
male default level)
Combined programme is similar to UN/Sal females. Rescued
males maintain a steady body composition on a normal chow
diet but show elevated weight gain on HF diet.
1The thrifty metabolic programme is induced by periods of restricted growth, whether due to maternal undernutrition or postnatal leptin treatment, and is
consequently present in all except AD/Sal cohorts.
2The level of the set point is established by the body composition at the time of the neonatal leptin surge, and is consequently normal for AD cohorts and lean
for UN cohorts.
3The strength with which the set point calibration is enforced depends on the levels of leptin at the time of calibration. Set point enforcement is weaker in males
than in females for unknown reasons.
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varies considerably between cohorts. The AD/Sal and AD/
Lep cohorts have a normal body composition at the time
of leptin stimulation and thus are calibrated to a normal
set point. The UN/Lep cohorts have a very lean body
composition at the time of leptin stimulation and thus are
calibrated to a lean set point. The UN/Sal cohorts also
have a lean body composition postnatally and are there-
fore calibrated to a lean set point, but since there is no ex-
ogenous leptin given and endogenous levels are low, the
calibration is only weakly enforced. Consequently, in the
UN/Lep cohort the set point mechanisms are strong
enough to over-ride the metabolic programme and
enforce a lean body composition, masking the thrifty
hepatic metabolic programming, while in the UN/Sal co-
hort they cannot do so. In males the hepatic element of
the programme is maintained, while the set point enforce-
ment is weaker for unknown reasons.
The new model thus explains four key puzzles con-
cerning various features of the programmed phenotypes
in males and females of this rat model, namely;
(1) In females AD/Lep and UN/Sal both induce
transcriptional changes related to fatty liver disease,
but the combination of both in UN/Lep does not
(Figure 1 and Results passim).(2) AD/Lep treatment is obesogenic in males but not in
females (Figure 3A).
(3) Neonatal leptin treatment protects against metabolic
syndrome in UN females on a high fat postweaning
diet, but is much less effective in males (Figure 3A).
(4) UN/Sal/Chow females maintain a constant weight
relative to AD/Sal/Chow controls from weaning
onwards, whereas UN/Sal/Chow males shows a
lifelong slow increase relative to AD/Sal/Chow
controls (Figure 3B).
Significance of the “calibration” model for postnatal
leptin signalling
Potentially this view of postnatal leptin signalling as a
training/calibration mechanism is also applicable in wider
contexts. For example, maternal overnutrition (as well as
undernutrition) can also programme metabolic syndrome
and obesity in offspring [21]. Under our model, this is ex-
plained by the offspring being fatter at the time of the
postnatal leptin training signal. The set point is conse-
quently established at a higher level, leading these individ-
uals to maintain and defend an inappropriately high body
fat composition.
Similarly, this model could explain the differences in
outcome (seen in both human and animal models) be-
tween neonates exhibiting rapid catch-up growth after
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weight [30,31]. Given that rapid weight recovery leads
disproportionately to fat gain rather than lean tissue
gain, it will skew the overall body composition to a higher
fat percentage, which will subsequently be “locked in”
once the leptin signalling reaches a high enough level to
trigger the establishment of a body composition set point.
Consistent with this, in a rat model, rapid catch up growth
leads to leptin resistance in adulthood–the reduced sensi-
tivity will consequently lead these animals to self-regulate
to a higher plasma leptin level and a higher body fat con-
tent. Conversely, slower catch up growth does not have
the same effect on the leptin feedback loop [32,33].
Of key interest for future research will be whether this
post-natal calibration of the body’s set point is a one-off
event during a specific developmental window, or whether
it can be re-triggered by a leptin surge (endogenous or ex-
ogenous) at later ages. One can envisage a “ratchet” mech-
anism for morbid obesity whereby weight gain beyond a
given threshold triggers a re-calibration and establishment
of a “new normal”, making subsequent weight loss harder.
Conversely, if “surge” levels of leptin were administered
following a period of weight loss, would it then be able to
re-establish a healthier set point for the patient?
A thrifty liver is an immunosuppressed, inflamed liver
In functional terms, there are two core axes affected by
the phenotypic switch in the liver, namely metabolism-
and immune-related functions. The metabolism-related
changes include upregulation of multiple genes concerned
with mitochondrial function, glycolysis, gluconeogenesis
and carbohydrate metabolism. This is associated with in-
creased total body fat percentage, increased circulating
fasting leptin levels, and increased insulin/C-peptide levels.
The second functional cluster of expression changes
observed relates to immune function, with a concerted
downregulation of MHC genes (predominantly class I
genes, but also some class Ib and class II genes) and the
Tap2 peptide transporter necessary for antigen presenta-
tion by class I molecules. Concurrent with this downreg-
ulation of adaptive immunity, there is a trend towards
upregulation of the innate immune system, including both
generic inflammatory mediators such as complement and
also liver-specific markers such as alpha-fetoprotein. These
changes are consistent with a model of non-alcoholic
fatty liver disease as a chronic low-grade inflammatory
process [34].
Concurrent with the pro-inflammatory changes ob-
served, the effects on the adaptive immune system are
interesting in relation to the immunological effects of
perinatal programming, in particular the increased mor-
tality from infectious disease in in utero-deprived chil-
dren [13,14]. Mechanistically, there is a plausible link
between the metabolic phenotype and the immune systemchanges in that excess saturated fatty acids are known to
exert an immunosuppressive effect via reduced antigen
presentation by MHC class I molecules [35-37]. Poten-
tially therefore this rat model may in future serve as a
model for immune system development in malnourished
children, as well as for metabolic disease.
It is intriguing to note that these transcriptional
changes–both those reflecting increased inflammation
and those reflecting decreased antigen presentation–are
not only seen in the UN/Sal/HF cohort, but are consist-
ent across all AD/Lep and UN/Sal cohorts irrespective
of postweaning diet. This suggests that the immune
changes are directly associated with the thrifty pheno-
type itself rather than with metabolic syndrome. An im-
portant avenue for future research will therefore be to
examine immune parameters at early timepoints in pro-
grammed thrifty and non-thrifty animals to confirm
whether the immune changes do indeed precede the de-
velopment of clinical disease, and what impact this has
for our understanding of the pathogenesis of obesity.
Do variations in hepatic thriftiness affect predisposition
to metabolic syndrome in a nutritionally rich
environment?
In the female experiment analysed here, despite the fact
that both AD/Lep and UN/Sal provoke the same thrifti-
ness phenotypic switch within the liver, it is only the
UN/Sal rats that subsequently develop the full hallmarks
of metabolic syndrome when fed a high fat diet. As we
argue above, we believe this is most likely due to non-
hepatic effects of leptin in establishing and maintaining
a set point for body composition, however it is also
plausible that there may be varying degrees of hepatic
thriftiness depending on the nature and intensity of the
stimulus provoking the programmed changes.
Therefore, we looked in detail at genes most strongly
associated with pathological status (i.e. genes where UN/
Sal/HF is an outlier from all other cohorts) and which
were also affected by the maternal diet/leptin inter-
action. These are the genes most strongly associated
with the induction of metabolic syndrome by maternal
undernutrition and its subsequent rescue by leptin treat-
ment. These too showed disturbances of carbohydrate
metabolism and an increase in gluconeogenesis. Strik-
ingly, around a quarter of this final set of genes showed
precursor changes in the UN/Sal/Chow cohort, which
potentially represent pre-pathogenic events that predis-
pose to metabolic syndrome even among rats on a nor-
mal diet. Further investigation of this cohort could
potentially indicate biomarkers for those at risk of meta-
bolic syndrome, allowing targeted intervention and/or
advice to be given before the onset of pathological
change. Conversely, investigation of the non-hepatic ef-
fects of leptin in the AD/Lep/HF cohort (at least in
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metabolic syndrome even in the presence of a thrifty
hepatic phenotype.
Conclusions
In this study, we have established that both prenatal un-
dernutrition and postnatal leptin treatment lead to a
thrifty liver programme, and explain this as a nonspecific
response to growth restriction from any cause. We fur-
ther show that this thrifty programming is associated
with increased expression of inflammatory markers and
also with a downregulation of antigen presentation genes
that may thus lead to immunosuppression. We propose
a new model for developmental programming of obesity
involving competing thriftiness and set point programmes,
which resolves several conflicts between the data from
male and female rats, and may apply more generally to
other models of obesogenic programming.
Methods
Liver samples
The experimental design utilised in this study has been
described previously [17-19]. Briefly, virgin Wistar rats
were time-mated and assigned to two nutritional groups:
ad-libitum (AD) or undernourished (UN, 30% of ad-
libitum). After birth, female AD and UN pups were ran-
domized to receive either saline (Sal) or recombinant rat
leptin (Lep, 2.5 μg/g · d) on neonatal days 3-13. After
weaning (day 22), saline-or leptin-treated AD and UN off-
spring were weight matched and placed on either standard
rat chow or a high fat (HF) chow (Research Diets No.
12451; 45% energy as fat) for the remainder of the study.
At postnatal day 170 rats were fasted overnight and killed
by halothane anaesthesia followed by decapitation. This
results in a balanced factorial 2×2×2 design with 8 treat-
ment groups, n = 8 animals per group. Liver samples were
immediately removed (collected from the same lobe) and
immediately snap frozen in liquid nitrogen and stored
at−80°C for later analysis. Time of culling was rotated
within and between groups to avoid circadian con-
founders, and was restricted to a narrow window be-
tween 9-11 am, at the start of the light phase of the
standard 12/12 dark/light cycle.
RNA extraction
RNA from whole liver tissue was prepared using Trizol
reagent (Sigma) according to the manufacturer’s proto-
col. Briefly, for each individual, 25 mg of frozen liver
tissue was homogenised in 1 ml Trizol, followed by
chloroform extraction. The aqueous supernatant con-
taining the RNA was retained and the RNA precipi-
tated with isopropanol. RNA pellets were washed with
50% ethanol, air dried and resuspended in RNAse-free
water (Milli-Q). RNA concentration and integrity wasassayed with a Nanodrop 1000 spectrophotometer and an
Agilent 2100 bioanalyser.
Microarray hybridisation and scanning
Array profiling was performed using the RatRef-12
oligonucleotide platform (Illumina). This comprises 21,910
probes covering the vast majority of the rat transcrip-
tome. Probe labelling, hybridisation, washing and scan-
ning were performed according to the manufacturer’s
protocols using the Illumina Total Prep kit (Applied
Biosystems). Briefly, first strand cDNA was synthesised
in a total volume of 20 μl with the supplied reagents.
The complete first strand product was used for second
strand synthesis, followed by column purification. The
purified product was then used for in vitro transcrip-
tion using T7 polymerase. Biotin-16-dUTP was incorpo-
rated during this step, resulting in a biotinylated cRNA
(complementary RNA) probe suitable for hybridisation.
Probe integrity was verified using the Nanodrop 100
and Agilent 2100, as for the initial RNA samples. Labelled
cRNA (1.5 μg) was hybridised to the array overnight at
55°C in a total volume of 30 μl of the manufacturer’s hy-
bridisation buffer, followed by post-hybridisation stringency
washing and scanning (BeadArray Reader, Illumina) using
the manufacturer’s standard protocols.
Data extraction and QC
Array data was extracted and presence/absence calls
performed using BeadStudio (Illumina), and subsequently
normalised in Lumi using a variance-stabilising transform-
ation. For each set of eight measurements for each gene/
experimental condition combination, the single measure-
ment furthest from the mean was excluded. This has the
effect of robustly eliminating noisy outlier measurements
while maintaining a fully balanced experimental design.
After outlier exclusion, an initial filter was applied to re-
move non-expressed genes (defined as those called as ab-
sent in > =75% of the data set). This reduced the initial set
of 21,910 probes to 8,497 liver-expressed genes for further
analysis.
ANOVA analysis, gene classification and filtering
One-way ANOVA analysis and gene list filtering was per-
formed using Kensington Discovery Edition (Inforsense).
Benjamini/Hochberg correction was used to control for
multiple testing, with a 5% false discovery rate (FDR). This
yielded a list of 2221 probes showing significant regulation
in at least one experimental cohort. Following Zhou et al.
2011 [38], these genes were then classified via a three-way
ANOVA looking at all three experimental factors (A =ma-
ternal diet, B = leptin treatment, C = postweaning diet)
and all four potential interaction terms (AB/BC/AC/ABC
interactions). Three-way ANOVA was performed using
GNU Octave.
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after FDR correction were assigned to group ABC. Next,
genes with no significant three-way interaction, but where
one or more of the two-way interaction terms was signifi-
cant after FDR correction were assigned to groups AB/
AC/BC as appropriate. Finally, genes with significant
effects for each individual experimental factor and no
confounding interaction term were assigned to groups
A/B/C as appropriate. The categories are not necessarily
exclusive: for example a gene showing additive non-
interacting effects of both maternal diet and leptin treat-
ment is included in both categories A and B. However, a
gene with a significant interaction term, i.e. where both
factors are significant but the effects do not combine
linearly, would instead fall into category AB. This iterative
method of classification ensures that a gene is only in-
cluded in a given category if there are no confounding
higher-order interaction terms.
DAVID analysis
DAVID analysis was performed using the web inter-
face available at http://david.abcc.ncifcrf.gov/summary.jsp
using default parameters for clustering stringency and the
Illumina rat chipset (RatRef-12_V1_0_R4_11222119_A) as
the reference list from which to calculate functional clus-
ter enrichment.
Phenotypic measurements
Plasma leptin was measured by in-house radioimmuno-
assay as described previously (Vickers et al., Endocrinology
2001). Fasting plasma insulin, C-peptide and total ghrelin
were measured using commercially available kits (rat insu-
lin ELISA, Cat# 10-1124-10; Mercodia, Uppsala, Sweden;
C-peptide RIA, cat# RCP-21 K; Linco Research Inc., St.
Charles, MO; Ghrelin RIA, cat# GHRT-89HK, Linco
Research). Fasting plasma glucose was measured using a
YSI glucose analyzer (Model 2300; Yellow Springs Instru-
ment Co., OH, USA). Plasma FFAs, glycerol and triglycer-
ides were measured in-house using standard colorimetric
assays.
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